Virtu Financial’s Ocular Therapeutix OCUL Stock Holding History

Virtu Financial’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$377K	Sell	44,560 -21,067	-32%	-$201K	0.02%	708
2025 Q4	$797K	Buy	65,627 +54,117	+470%	+$657K	0.03%	430
2025 Q3	$135K	Buy	+11,510	New	+$138K	0.01%	990
2024 Q1	–	Sell	-62,066	Closed	-$277K	–	1892
2023 Q4	$277K	Buy	+62,066	New	+$184K	0.02%	634
2023 Q3	–	Sell	-13,383	Closed	-$69K	–	1705
2023 Q2	$69K	Buy	+13,383	New	+$79.6K	0.01%	1094
2021 Q3	–	Sell	-12,641	Closed	-$179K	–	1826
2021 Q2	$179K	Sell	12,641 -3,297	-21%	-$50.1K	0.02%	1043
2021 Q1	$262K	Buy	+15,938	New	+$307K	0.02%	892
2020 Q4	–	Sell	-19,459	Closed	-$148K	–	1687
2020 Q3	$148K	Buy	+19,459	New	+$162K	0.03%	654
2019 Q4	$189K	Buy	47,820 +37,735	+374%	+$131K	0.02%	959
2019 Q3	$31K	Buy	+10,085	New	+$45.1K	﹤0.01%	1250
2018 Q3	–	Sell	-20,672	Closed	-$140K	–	1988
2018 Q2	$140K	Buy	20,672 +533	+3%	+$3.66K	0.01%	1589
2018 Q1	$131K	Sell	20,139 -42,881	-68%	-$241K	0.01%	1508
2017 Q4	$280K	Buy	+63,020	New	+$322K	0.01%	1328

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Virtu Financial's OCUL Position: Q1 2026 in Review

Virtu Financial reduced its Ocular Therapeutix (OCUL) stake by 32% in Q1 2026, selling an estimated $201K and leaving 44,560 shares worth $377K. The position accounts for 0.02% of the portfolio, ranked #708.

Virtu Financial first reported a position in OCUL in Q4 2017 and has held it in 13 quarters since. The position peaked at $797K in Q4 2025. 269 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

Virtu Financial held 44,560 shares of Ocular Therapeutix worth $377K as of Q1 2026.
Virtu Financial sold 21,067 Ocular Therapeutix shares in Q1 2026, an estimated $201K.
Ocular Therapeutix made up 0.02% of Virtu Financial's portfolio in Q1 2026, its #708 holding.
Virtu Financial first reported a position in Ocular Therapeutix in Q4 2017 and has held it in 13 quarters since.
Virtu Financial's Ocular Therapeutix position peaked at $797K in Q4 2025.
269 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on Virtu Financial's 13F filing for Q1 2026, filed 14 May 2026.